Simbiosys Raises $15 Million Series A To Develop The Future Of Precision Cancer Care
Amount Raised
$15 Million
Round Type
Series A
ChicagoBiotechnologyDescription
SimBioSys announced today it raised $15 million in Series A funding to accelerate the development and commercialization of its TumorScope software platform. The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients. This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic. Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21 million.
Who to call at SimBioSys, and when
A new round usually means SimBioSys is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day SimBioSys raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at SimBioSys, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at SimBioSys. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment SimBioSys raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSimBioSys raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.